We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Faster Way of Detecting Bacteria Developed

By LabMedica International staff writers
Posted on 16 Feb 2017
A faster way to detect the pathogenic bacteria that may cause patients to become sick has now been developed, giving physicians a better chance at saving lives by proscribing the most suitable antibiotic.

Today, patients generally have to wait days to get final test result, but the new method of testing of urine samples, for example, produces positive results in two hours from start to finish versus the days it can take for equivalent hospital laboratory tests.

Scientists at Michigan State University developed a point-of-care diagnostic test known as In-Dx. More...
The detection process is relatively simple for both the patient and physician. A sample is collected and concentrated into a smaller amount. After applying heat, which breaks down the sample cells, it is then placed into the In-Dx testing panel and after 20 minutes of incubation time, the positive sample changes color, revealing the invading organism. The team is more than one year into a clinical trial that aims to validate the point-of-care diagnostic test, and the preliminary results already look promising.

The molecular diagnostic system can identify dangerous bacteria such as Escherichia coli, Staphylococcus infections, and even some superbugs. The test can produce results within two hours using blood, urine, saliva, wound, stool or cerebral spine fluid samples from infected patients. The team have concentrated on sepsis, a serious, life-threatening infection occurring more commonly in hospitalized patients, is one of the medical problems. If not treated properly, septic patients may have only hours to live. Currently, millions of people die each year worldwide partly because a definitive diagnosis of the sepsis-causing bacteria often takes too long.

Brett Etchebarne, MD, PhD, an assistant professor of emergency medicine, who helped develop the test said, “In-Dx has high sensitivity and specificity for detection of the most common infectious organisms which will help physicians quickly rule in or rule out specific bacteria. Knowing what your target is early in the fight against sepsis will be an invaluable advantage in helping maximize patient care strategies and outcomes.”


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.